Difference between revisions of "Custirsen (OGX-011)"

Latest revision as of 01:00, 27 June 2024

General information

Class/mechanism: Clusterin inhibitor. Clusterin is upregulated in cancer cells in response to antineoplastic treatment and is hypothesized to play a role in cancer cell survival and treatment resistance. Increased clusterin production has been associated with increased rates of progression, treatment resistance, and shorter survival. Inhibiting clusterin is hypothesized to decrease the rates of tumor growth and resistance to other treatments.^[1]^[2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, UpToDate (courtesy of Lexicomp), or the prescribing information.

Preliminary data

Non-small cell lung cancer

Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 2012 Mar;7(3):579-86. PubMed

Prostate cancer

Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. Epub 2011 Jul 25. PubMed

Patient drug information

No information available.

Also known as

Code name: OGX-011

References

[1] OncoGeneX Custirsen page

[2] Experimental Drug Receives Fast Track Designation as Second-Line Chemotherapy for Metastatic Castration-Resistant Prostate Cancer, ASCO Post, 4/23/2014

[1]

[2]

@@ Line 1: / Line 1: @@
 ==General information==
-Class/mechanism: Clusterin inhibitor.  Clusterin is upregulated in cancer cells in response to antineoplastic treatment and is hypothesized to play a role in cancer cell survival and treatment resistance.  Increased clusterin production has been associated with increased rates of progression, treatment resistance, and shorter survival.  Inhibiting clusterin is hypothesized to decrease the rates of tumor growth and resistance to other treatments.<ref>[http://www.oncogenex.com/physicians/custirsen-ogx-011 OncoGeneX Custirsen page]</ref><ref>[http://www.ascopost.com/ViewNews.aspx?nid=16150 Experimental Drug Receives Fast Track Designation as Second-Line Chemotherapy for Metastatic Castration-Resistant Prostate Cancer, ASCO Post, 4/23/2014]</ref>
+Class/mechanism: Clusterin inhibitor. Clusterin is upregulated in cancer cells in response to antineoplastic treatment and is hypothesized to play a role in cancer cell survival and treatment resistance. Increased clusterin production has been associated with increased rates of progression, treatment resistance, and shorter survival. Inhibiting clusterin is hypothesized to decrease the rates of tumor growth and resistance to other treatments.<ref>[http://www.oncogenex.com/physicians/custirsen-ogx-011 OncoGeneX Custirsen page]</ref><ref>[http://www.ascopost.com/ViewNews.aspx?nid=16150 Experimental Drug Receives Fast Track Designation as Second-Line Chemotherapy for Metastatic Castration-Resistant Prostate Cancer, ASCO Post, 4/23/2014]</ref>
 <br>Route: IV
 <br>Extravasation: no information
-For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
+For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
-==Clinical trials==
+==Preliminary data==
-*[http://clinicaltrials.gov/ct2/show/NCT01578655 Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)]
+===[[Non-small cell lung cancer]]===
-*[http://clinicaltrials.gov/ct2/show/NCT01188187 Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)]
+# Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 2012 Mar;7(3):579-86. [https://pubmed.ncbi.nlm.nih.gov/22198426/ PubMed]
-*[http://clinicaltrials.gov/ct2/show/NCT01630733 A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer]
+===[[Prostate cancer]]===
+# Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. Epub 2011 Jul 25. [https://pubmed.ncbi.nlm.nih.gov/21788353/ PubMed]
 ==Patient drug information==
 No information available.
+==Also known as==
+*'''Code name:''' OGX-011
 ==References==
 <references/>
-[[Category:Drug index]]
+[[Category:Drugs]]
-[[Category:Investigational]]
+[[Category:Intravenous medications]]
+[[Category:Clusterin inhibitor]]
+[[Category:Non-small cell lung cancer medications (investigational)]]
+[[Category:Prostate cancer medications (investigational)]]
+[[Category:Investigational drugs]]